Comparative effectiveness of HIV testing and treatment in highly endemic regions

Archives of Internal Medicine

Volumn 170, Issue 15, 2010, Pages 1347-1354

  Bendavid, Eran ^a   Brandeau, Margaret L ^b   Wood, Robin ^a,c   Owens, Douglas K ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b Stanford University   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AFRICA; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MALE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ENDEMIC DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MEDICAL RECORD LINKAGE; PREVALENCE; SOUTH AFRICA; YOUNG ADULT;

EID: 77955444781     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.249     Document Type: Article

References (48)

1. UNAIDS. Report on the Global AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2008.
2. UNAIDS. AIDS Epidemic Update. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2007.
3. Gregson S, Garnett GP, Nyamukapa CA, et al. HIV decline associated with behavior change in eastern Zimbabwe. Science. 2006;311(5761):664-666. (Pubitemid 43191311)
4. Dixon S, McDonald S, Roberts J. The impact of HIV and AIDS on Africa's economic development. BMJ. 2002;324(7331):232-234. (Pubitemid 34107096)
5. UNAIDS/World Health Organization. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report. Geneva, Switzerland: UNAIDS/World Health Organization; 2009.
6. UNAIDS. Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support. Geneva, Switzerland: UNAIDS; 2007.
7. UNAIDS/World Health Organization. Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities. Geneva, Switzerland: UNAIDS/World Health Organization; 2007.
8. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296 (7):782-793. (Pubitemid 44223102)
9. Brinkhof M, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE. 2009;4(6):e5790.
10. Granich RM, Gilks C, Dye C, De Cock K, Williams B. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57.
11. A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. HIV Prevention Trials Web site. http://www.hptn.org/research-studies/HPTN052.asp. Accessed June 12, 2009.
12. Bassett IV, Giddy J, Wang B, et al. Routine, voluntary HIV testing in Durban, South Africa: correlates of HIV infection. HIV Med. 2008;9(10):863-867.
13. Bassett I, Regan S, Chetty S, et al. Who starts ART in Durban, South Africa? not everyone who should [abstract WEAD102]. Conference of International AIDS Society; July 19-22, 2009; Cape Town, South Africa.
14. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298.
15. US Census Bureau International Data Base. US Census Bureau Web site. http: //www.census.gov/ipc/www/idb/tables.html. Accessed July 15, 2009.
16. Shisana O, Rehle T, Simbayi L, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey: A Turning Tide Among Teenagers? Cape Town, South Africa: HSRC Press; 2008.
17. Parker W, Makhubele B, Ntlabati P, Connolly C. Concurrent Sexual Partnerships Amongst Young Adults in South Africa: Challenges for HIV Prevention Communication. Johannesburg, South Africa: CADRE; 2007.
18. Williams BG, Lloyd-Smith JO, Gouws E, et al. The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med. 2006;3(7):e262.
19. World Health Organization life tables for WHO member states. World Health Organization Web site. http://www.who.int/whosis/database/life-tables/life- tables.cfm. Accessed July 15, 2009,.
20. Demographic and Health Survey, ORC Macro. http://www.measuredhs.com. Accessed May 1, 2010.
21. Connolly C, Simbayi L, Shanmugam R, Nqeketo A. Male circumcision and its relationship to HIV infection in South Africa: results from a national survey in 2002. S Afr Med J. 2009;98(10):789-794.
22. Dorrington R, Johnson L, Bradshaw D, Daniel T. The Demographic Impact of HIV/AIDS in South Africa: National and Provincial Indicators for 2006. Cape Town, South Africa: Centre for Actuarial Research, South African Medical Research Council and Actuarial Society of South Africa; 2006.
23. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005; 191(9):1403-1409.
24. Gray RH, Wawer MJ, Brookmeyer R, et al; Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149-1153.
25. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921-929.
26. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.
27. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369(9562):643-656.
28. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657-666.
29. Kamb ML, Fishbein M, Douglas JM Jr, et al; Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA. 1998; 280(13):1161-1167.
30. + cell count distributions in African populations. J Infect Dis. 2006;194(10):1450-1458.
31. Auvert B, Males S, Puren A, Taljaard D, Caraël M, Williams B. Can highly active antiretroviral therapy reduce the spread of HIV? a study in a township of South Africa. J Acquir Immune Defic Syndr. 2004;36(1):613-621. (Pubitemid 38544511)
32. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8:89. (Pubitemid 352025050)
33. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? a South African cost-effectiveness study. Antivir Ther. 2006;11(1):63-72. (Pubitemid 43306078)
34. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12 (1):83-88. (Pubitemid 46340429)
35. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42(4):464-469. (Pubitemid 44050895)
36. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368(9543):1254-1259. (Pubitemid 44508698)
37. Lawn SD, Little F, Bekker L, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23(3):335-342.
38. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19(14):1525-1534. (Pubitemid 41400699)
39. April M, Walensky R, Chang Y, et al. Trends in HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. In: Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Quebec, Canada.
40. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GM, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a Southern African analysis. Arch Intern Med. 2008;168(17):1910-1918.
41. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings-a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2009;52(1):106-113.
42. De Cock KM. Plenary talk. HIV Implementers' Meeting; June 10, 2009; Windhoek, Namibia.
43. 2008 Report on the global AIDS epidemic: epidemiology information. Joint United Nations Programme on AIDS Web site. http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp. Accessed November 2008.
44. WHO Mortality Database. http://www.who.int/healthinfo/morttables/en/. Accessed June 29, 2009.
45. Walensky R, Wolf L, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009;151(3):157-166.
46. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Bulletin des Médecins Suisses. 2008;89 (5):165-169.
47. Reynolds S, Makumbi F, Kagaayi J, et al. ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda. Presented at: Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Quebec, Canada.
48. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ. 2006;332(7541):605-607.